The challenge of osteoporosis in CKD
Join this educational event organised by EUROD, a CKD-MBD Working Group initiative, in collaboration with the International Osteoporosis Foundation (IOF) to be held on January 18, 2019 in Leuven (Belgium). Updates on the clinical assessment and treatment of osteoporosis in CKD anno 2019 will be presented through state of the art lectures given by key opinion leaders and the interactive voting system encouraging discussion.
Click here to download the full programme.
Click here to register.
NEW !!!
This educational event was granted with has been granted
4 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).
Are you a young ERA-EDTA member? Apply for travel grant?
Click here to read the regulations and download the relevant form

This meeting is organised in collaboration with the International Osteoporosis Foundation

The ERA-EDTA Council recently approved the creation of a working group dedicated to Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). This acronym, or its translation, has been increasingly endorsed by different Nephrology Societies and International initiatives, including both the KDIGO (Kidney Disease Improving Global Outcomes) and the EBPG (European Best Practice Guidelines).

The definition of CKD-MBD is different than the previously recognized as "renal osteodystrophy", and it refers to a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following:

  • Abnormalities of calcium, phosphorus, parathyroid hormone (PTH), or vitamin D metabolism.
  • Abnormalities in bone turnover, mineralization, volume, linear growth, or strenght.
  • Vascular or other soft-tissue calcification.

The term "renal osteodystrophy" is now limited to an alteration of bone morphology in patients with CKD, and it is one measure of the skeletal component of the systemic disorder of CKD-MBD that is quantifiable by histomorphometry of bone biopsy.

image 1


Thus, the CKD-MBD Working Group becomes an independent scientific organization comprising a group of European academic medical institutions aligned to CKD-MBD regarding:

  • Enhancing the scientific understanding and preclinical background.
  • Analyzing the clinical implications.
  • Elaborating therapeutic options.
Special emphasis is on:
  • Increasing research collaborations.
  • Promote education for Fellows and Faculty.
  • Improve scientific communication and dissemination of knowledge in the field.


As per the ERA-EDTA regulations for Working groups, the vision and mission of the CKD-MBD Working Group are:

  • To promote and organize pan-European independent research in the field of CKD-MBD including both basic, translational and clinical research.
  • To improve and distribute knowledge in the field of CKD-MBD (appropriate therapies, Guidelines, etc.).
  • To address particular research questions that have not and may not be addressed by usual means.
  • To organize a structured educational process and program for young researchers in the field of CKD-MBD allowing them to start networking and exchange expertise.
  • To collaborate to the organization of educational activities of the ERA-EDTA.
  • To develop training concepts for both clinical as well as research activities throughout Europe.
  • To organize an annual meeting focusing on educational themes and on research proposals.
  • To organize an annual meeting during the annual ERA-EDTA Congress, to be included in the Scientific Program.